{"": [129, 138, 0, 139, 1805, 0], "Introduction": [1806, 5890, 0], "Study design and animals": [5914, 6809, 0], "Cell lines and viruses": [6810, 7769, 0], "Confirmation of key characteristics of K562 cells": [7770, 8593, 0], "Construction, verification, and characterization of K562-S vaccine": [8594, 11886, 0], "Inactivation of K562-S cells for vaccine preparation": [11887, 12767, 0], "Animal experiments": [12768, 13843, 0], "Immunization and challenge of mice": [13844, 15659, 0], "Immunization of rhesus macaques": [15660, 16681, 0], "Enzyme-linked immunosorbent assay (ELISA)": [16682, 18700, 0], "IFN-gamma ELISpot assay": [18701, 20153, 0], "Human convalescent serum": [20154, 20625, 0], "Pseudovirus neutralization assay": [20626, 22444, 0], "Authentic neutralization assay": [22445, 23232, 0], "Quantitative reverse transcription polymerase chain reaction (qRT-PCR)": [23233, 24427, 0], "Histopathology": [24428, 25020, 0], "Statistical analyses": [25021, 25754, 0], "Materials and methods": [5891, 25754, 1], "Design and construction of human K562 cell-based vaccine": [25764, 26933, 0], "Inactivation methods for production of K562-S vaccines with maintained immunogenicity": [26934, 30481, 0], "Enhancing effect on immune response to K562-S vaccine by adjuvants": [30482, 33636, 0], "Impact of storage condition on the efficacy of K562-S-FI vaccine in mice": [33637, 34338, 0], "K562-S vaccination-mediated protection against SARS-CoV-2 challenge in hACE2 transgenic mice": [34339, 39272, 0], "Evaluation of K562-S-FI vaccines in non-human primate animal model": [39273, 44876, 0], "Results": [25755, 44876, 1], "Discussion": [44877, 57720, 0], "Limitations of study": [57721, 60196, 0], "Supplementary Material": [60197, 60259, 0]}